Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice

Cancer and Metastasis Reviews

Volumn 35, Issue 1, 2016, Pages 141-150

  Pirker, Robert ^a   Filipits, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ALK; Biomarker; Cetuximab; EGFR mutations; Liquid biopsy; Necitumumab

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; ATEZOLIZUMAB; AVELUMAB; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DNA FRAGMENT; DOCETAXEL; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; IPILIMUMAB; MICROTUBULE ASSOCIATED PROTEIN; NECITUMUMAB; NINTEDANIB; NIVOLUMAB; OSIMERTINIB; PACLITAXEL; PEMBROLIZUMAB; ROCILETINIB; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PALLIATIVE THERAPY; CLINICAL PRACTICE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID BIOPSY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84960412692     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-016-9612-6     Document Type: Article

References (65)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359–386.
2. Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26, 3543–3551.
3. Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 22, 2184–2191.
4. Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H., Beasley, M. B., et al. (2015). The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of Thoracic Oncology, 10, 1243–1260.
5. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., et al. (2013). Signatures of mutational processes in human cancer. Nature, 500, 415–421.
6. Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., et al. (2012). Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell, 150, 1107–1120.
7. Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 55, 1069–1075.
8. Cancer Genome Atlas Research Network. (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511, 543–550.
9. Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., et al. (2012). Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 150, 1121–1134.
10. Cancer Genome Atlas Research Network. (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489, 519–525.
11. Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., et al. (2012). Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 44, 1104–1110.
12. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., et al. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England Journal of Medicine, 373, 1627–1639.
13. Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine, 372, 2018–2028.
14. Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England Journal of Medicine, 355, 983–991.
15. Friboulet, L., Olaussen, K. A., Pignon, J. P., Shepherd, F. A., Tsao, M. S., Graziano, S., et al. (2013). ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. The New England Journal of Medicine, 368, 1101–1110.
16. Massuti, B., Cobo, M., Rodriguez-Paniagua, J.M., Ballesteros, A.I., Moran, T., Arrabal, R., et al. (2015). Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial. Journal of Clinical Oncology, 33, (suppl; abstr 7507).
17. Soria, J. C., Mok, T. S., Cappuzzo, F., & Jänne, P. A. (2012). EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treatment Reviews, 38, 416–430.
18. Pirker, R. (2015). What is the best strategy for targeting EGF receptors in non-small-cell lung cancer? Future Oncology, 11, 153–167.
19. Pirker, R. (2015). Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update. Current Opinion in Oncology, 27, 87–93.
20. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101, 13306–13311.
21. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 350, 2129–2139.
22. Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497–1500.
23. Yang, J. C., Wu, Y. L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., et al. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16, 141–151.
24. Azzoli, C. G., Baker, S., Jr., Temin, S., Pao, W., Aliff, T., Brahmer, J., et al. (2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 27, 6251–6266.
25. Pirker, R., Herth, F. J., Kerr, K. M., Filipits, M., Taron, M., Gandara, D., et al. (2010). Consensus for EGFR mutation testing in non-small cell lung cancer: results from a european workshop. Journal of Thoracic Oncology, 5, 1706–1713.
26. Popper, H., Wrba, F., Gruber-Mösenbacher, U., Hulla, W., Pirker, R., Hilbe, W., et al. (2011). Histology-based algorithm in the molecular diagnosis of mutations of the epidernal growth factor receptor (EGFR) in non-small cell lung cancer. Wiener Klinische Wochenschrift, 123, 316–321.
27. Felip, E., Gridelli, C., Baas, P., Rosell, R., Stahel, R., & Panel Members. (2011). Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Annals of Oncology, 22, 1507–1519.
28. Soria, J. C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., et al. (2015). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. The Lancet Oncology, 16, 897–907.
29. Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., et al. (2011). Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research, 17, 1616–1622.
30. Camidge, D. R., Pao, W., & Sequist, L. V. (2014). Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Reviews. Clinical Oncology, 11, 473–481.
31. Janjigian, Y. Y., Smit, E. F., Groen, H. J., Horn, L., Gettinger, S., Camidge, D. R., et al. (2014). Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery, 4, 1036–1045.
32. Pircher, A., Manzl, C., Fiegl, M., Popper, H., Pirker, R., & Hilbe, W. (2014). Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient. Lung Cancer, 83, 408–410.
33. Walter, A. O., Sjin, R. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., et al. (2013). Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discovery, 3, 1404–1415.
34. Cross, D. A., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., et al. (2014). AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery, 4, 1046–1061.
35. Jänne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., et al. (2015). AZD9219 in EGFR inhibitor-resistant non-small-cell lung cancer. The New England Journal of Medicine, 372, 1689–1699.
36. Sequist, L. V., Soria, J. C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., et al. (2015). Rociletinib in EGFR-mutated non-small-cell lung cancer. The New England Journal of Medicine, 372, 1700–1709.
37. Kim, D. W., Lee, D. H., Kang, J. H., et al. (2014). Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). Journal of Clinical Oncology, 32, 5s.
38. Ercan, D., Choi, H. G., Yun, C. H., Capelletti, M., Xie, T., Eck, M. J., et al. (2015). EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clinical Cancer Research, 21, 3913–3923.
39. Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., et al. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature Medicine, 21, 560–562.
40. Ramlau, R., Cufer, T., Berzinec, P., Dziadziuszko, R., Olszewski, W., Popper, H., et al. (2015). Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: The INSIGHT study. Journal of Thoracic Oncology, 10, 1370–1374.
41. Schmid, K., Oehl, N., Wrba, F., Pirker, R., Pirker, C., & Filipits, M. (2009). EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clinical Cancer Research, 15, 4554–4560.
42. Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., et al. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 373, 1525–1531.
43. Pujol, J. L., Pirker, R., Lynch, T. J., Butts, C. A., Rosell, R., Shepherd, F. A., et al. (2014). Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer, 83, 211–218.
44. Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., et al. (2010). Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. Journal of Clinical Oncology, 28, 911–917.
45. Thatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., et al. (2015). Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. The Lancet Oncology, 16, 763–774.
46. Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., et al. (2015). Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. The Lancet Oncology, 16, 328–337.
47. Pirker, R., Pereira, J. R., von Pawel, J., Krzakkowski, M., Ramlau, R., Park, K., et al. (2012). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology, 13, 33–42.
48. Hirsch, F.R., Boyle, T.A., Thatcher, N., et al. (2015). EGFR IHC and FISH correlative analyses (SQUIRE trial): Necitumumab + gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC. 16th World Conference on Lung Cancer. Abstract ORAL32.05. Presented September 9, 2015.
49. Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., et al. (2008). Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. Journal of Clinical Oncology, 26, 3351–3357.
50. Herbst, R., Redman, M.W., Kim, E.S., et al. (2015). A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC): SWOG S0819. 16th World Conference on Lung Cancer. Abstract PLEN04.01. Presented September 9, 2015.
51. O’Byrne, K. J., Gatzemeier, U., Bondarenko, I., Barrios, C., Eschbach, C., Martens, U. M., et al. (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. The Lancet Oncology, 12, 795–805.
52. Khambata-Ford, S., Harbison, C. T., Hart, L. L., Award, M., Xu, L. A., Horak, C. E., et al. (2010). Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28, 918–927.
53. Gatzemeier, U., von Pawel, J., Vynnychenko, I., Zatloukal, P., de Marinis, F., Eberhardt, W. E., et al. (2011). First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. The Lancet Oncology, 12, 30–37.
54. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M. J., et al. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine, 368, 2385–2394.
55. Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371, 2167–2177.
56. Pall, G. (2015). The next-generation ALK inhibitors. Current Opinion in Oncology, 27, 118–124.
57. Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., et al. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine, 371, 1963–1971.
58. Sandler, A., Gray, R., Perry, M.C., Brahmer,.J, Schiller, J.H., Dowlati, A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine, 355, 2542–2550.
59. Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., et al. (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Journal of Clinical Oncology, 27, 1227–1234.
60. Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J. Y., Orlov, S., Krzakowski, M., et al. (2014). Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. The Lancet Oncology, 15, 143–155.
61. Vansteenkiste, J., Fehrenbacher, L., Spira, A.I., Mazieres, J., Park, K., Smith, D., et al. (2015). Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European Cancer Congress (ECC 2015), Vienna, LBA014.
62. Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., et al. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, S0169–5002(15), 30073–8.
63. Tseng, J. S., Yang, T. Y., Tsai, C. R., Chen, K. C., Hsu, K. H., Tsai, M. H., et al. (2015). Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. Journal of Thoracic Oncology, 10, 603–610.
64. Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O’Connell, A., Messineo, M. M., et al. (2014). Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clinical Cancer Research, 20, 1698–1705.
65. Sundaresan, T.K., Sequist, L.V., Heymach, J.V., Riely, G.J., Jänne, P.A., Koch, W.H., et al. (2015). Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clinical Cancer Research.